Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]PI-2620 PET in Alzheimer's Disease and MCI
NCT03903211Phase 2Completed
- Start
- Apr 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 18F-PI-2620 in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (3 arms). Primary endpoint: Standard Uptake Value Ratio. Started Apr 2019; status: completed.
02
Drugs
18F-PI-2620
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03903211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903211.